Logo image of ACXP

ACURX PHARMACEUTICALS INC (ACXP) Stock Fundamental Analysis

NASDAQ:ACXP - Nasdaq - US00510M1045 - Common Stock - Currency: USD

0.6235  -0.1 (-13.4%)

Fundamental Rating

2

ACXP gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 557 industry peers in the Biotechnology industry. While ACXP seems to be doing ok healthwise, there are quite some concerns on its profitability. ACXP has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year ACXP has reported negative net income.
ACXP had a negative operating cash flow in the past year.
In the past 5 years ACXP always reported negative net income.
In the past 5 years ACXP always reported negative operating cash flow.
ACXP Yearly Net Income VS EBIT VS OCF VS FCFACXP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -5M -10M

1.2 Ratios

With a Return On Assets value of -247.10%, ACXP is not doing good in the industry: 91.92% of the companies in the same industry are doing better.
The Return On Equity of ACXP (-513.73%) is worse than 78.99% of its industry peers.
Industry RankSector Rank
ROA -247.1%
ROE -513.73%
ROIC N/A
ROA(3y)-227.85%
ROA(5y)-184.53%
ROE(3y)-923.45%
ROE(5y)-608.69%
ROIC(3y)N/A
ROIC(5y)N/A
ACXP Yearly ROA, ROE, ROICACXP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -500 -1K -1.5K -2K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ACXP so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ACXP Yearly Profit, Operating, Gross MarginsACXP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

5

2. Health

2.1 Basic Checks

The number of shares outstanding for ACXP has been increased compared to 1 year ago.
The number of shares outstanding for ACXP has been increased compared to 5 years ago.
There is no outstanding debt for ACXP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ACXP Yearly Shares OutstandingACXP Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 5M 10M 15M
ACXP Yearly Total Debt VS Total AssetsACXP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

2.2 Solvency

Based on the Altman-Z score of -23.75, we must say that ACXP is in the distress zone and has some risk of bankruptcy.
ACXP has a Altman-Z score of -23.75. This is amonst the worse of the industry: ACXP underperforms 87.43% of its industry peers.
There is no outstanding debt for ACXP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -23.75
ROIC/WACCN/A
WACCN/A
ACXP Yearly LT Debt VS Equity VS FCFACXP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 5M -5M 10M -10M

2.3 Liquidity

ACXP has a Current Ratio of 1.93. This is a normal value and indicates that ACXP is financially healthy and should not expect problems in meeting its short term obligations.
ACXP's Current ratio of 1.93 is on the low side compared to the rest of the industry. ACXP is outperformed by 77.20% of its industry peers.
ACXP has a Quick Ratio of 1.93. This is a normal value and indicates that ACXP is financially healthy and should not expect problems in meeting its short term obligations.
ACXP's Quick ratio of 1.93 is on the low side compared to the rest of the industry. ACXP is outperformed by 75.76% of its industry peers.
Industry RankSector Rank
Current Ratio 1.93
Quick Ratio 1.93
ACXP Yearly Current Assets VS Current LiabilitesACXP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 40.17% over the past year.
EPS 1Y (TTM)40.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%60.71%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

ACXP is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 5.90% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y13.24%
EPS Next 2Y19.07%
EPS Next 3Y11.92%
EPS Next 5Y5.9%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ACXP Yearly Revenue VS EstimatesACXP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2025 2026 2027 2028 2029 2030 2031 20M 40M 60M 80M 100M
ACXP Yearly EPS VS EstimatesACXP Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 -0.5 -1 -1.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ACXP. In the last year negative earnings were reported.
Also next year ACXP is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ACXP Price Earnings VS Forward Price EarningsACXP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ACXP Per share dataACXP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4 -0.6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y19.07%
EPS Next 3Y11.92%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ACXP!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ACURX PHARMACEUTICALS INC

NASDAQ:ACXP (6/20/2025, 10:57:34 AM)

0.6235

-0.1 (-13.4%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-12 2025-05-12/amc
Earnings (Next)08-07 2025-08-07
Inst Owners14.91%
Inst Owner Change147.63%
Ins Owners10.95%
Ins Owner Change6.68%
Market Cap14.64M
Analysts82.22
Price Target5.81 (831.84%)
Short Float %1.41%
Short Ratio1.59
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)20.48%
Min EPS beat(2)12.85%
Max EPS beat(2)28.1%
EPS beat(4)3
Avg EPS beat(4)10.44%
Min EPS beat(4)-15.86%
Max EPS beat(4)28.1%
EPS beat(8)4
Avg EPS beat(8)-0.12%
EPS beat(12)7
Avg EPS beat(12)4.39%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)15.57%
PT rev (3m)-49.08%
EPS NQ rev (1m)0%
EPS NQ rev (3m)60.67%
EPS NY rev (1m)0%
EPS NY rev (3m)64.08%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 6.33
P/tB 6.33
EV/EBITDA N/A
EPS(TTM)-0.7
EYN/A
EPS(NY)-0.51
Fwd EYN/A
FCF(TTM)-0.4
FCFYN/A
OCF(TTM)-0.4
OCFYN/A
SpS0
BVpS0.1
TBVpS0.1
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -247.1%
ROE -513.73%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-227.85%
ROA(5y)-184.53%
ROE(3y)-923.45%
ROE(5y)-608.69%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.93
Quick Ratio 1.93
Altman-Z -23.75
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)40.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%60.71%
EPS Next Y13.24%
EPS Next 2Y19.07%
EPS Next 3Y11.92%
EPS Next 5Y5.9%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y26.03%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3Y3.95%
EBIT Next 5YN/A
FCF growth 1Y-23.48%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-23.48%
OCF growth 3YN/A
OCF growth 5YN/A